Mpox Vaccination Campaign Expands in Réunion as Madagascar Outbreak Fuels Regional Concerns
The seemingly contained threat of mpox has resurfaced, prompting swift action in Réunion Island. Following confirmed cases linked to travel from Madagascar, health authorities are launching a targeted vaccination campaign, highlighting a growing concern about regional spread and the evolving dynamics of this viral disease. This isn’t simply a repeat of past outbreaks; the current situation demands a proactive, multi-faceted approach to protect vulnerable populations and prevent wider transmission.
From Madagascar to Réunion: A Growing Pattern of Exportation
The first imported case in Réunion, confirmed on January 22, 2026, involved a resident returning from Madagascar. A second case, confirmed February 10, 2026, further underscores this pattern of exportation. Crucially, authorities have found no epidemiological link between the two cases, suggesting multiple, independent importations. This indicates a sustained level of transmission in Madagascar and a real risk of further spread to neighboring islands and beyond. Recent reports indicate a rapid increase in cases in Madagascar, reaching 533 total as of a few days ago, with the Mahajanga coastal region remaining the epicenter of the outbreak. BeaconBio has been tracking these exportations, emphasizing the potential for regional escalation.
Who is at Risk? Targeted Vaccination Strategies
Réunion’s health agency (ARS La Réunion) is prioritizing vaccination for those most at risk. The campaign, launched February 9, 2026, focuses on several key groups: immunocompromised individuals, men who have sex with men (MSM), and sex workers. Vaccination is also available on medical advice for travelers heading to Madagascar or areas with active virus circulation, including health professionals and humanitarian workers. A reactive vaccination strategy is also in place, offering vaccination to close contacts of confirmed cases, ideally within 4-14 days of exposure.
Key Takeaway: The tiered approach to vaccination reflects a pragmatic understanding of transmission pathways and risk factors, maximizing the impact of limited vaccine supplies.
Reactive Vaccination: A Critical Window of Opportunity
The emphasis on reactive vaccination is particularly noteworthy. Administering the vaccine within the first four days of exposure offers the highest level of protection, though it remains beneficial up to 14 days post-exposure. This highlights the importance of rapid contact tracing and prompt access to vaccination services. Vaccination is free for prioritized groups, but travelers to Madagascar will need to cover the cost of the vaccine itself.
Beyond Réunion: Regional Surveillance and the Mauritius Response
The situation in Réunion has prompted heightened vigilance across the region. Mauritius has already strengthened its surveillance measures in response to the increasing cases in Madagascar and the confirmed case in Réunion. This proactive approach is crucial to prevent further spread and protect vulnerable populations. Reports on Facebook indicate a growing awareness of the threat and a coordinated regional response.
The Future of Mpox: What to Expect
The current outbreak underscores several critical points about the future of mpox. First, the virus is not simply contained. Sporadic outbreaks, fueled by travel and specific risk factors, are likely to continue. Second, robust surveillance systems are essential for early detection and rapid response. Réunion’s enhanced surveillance system played a crucial role in identifying the imported cases. Third, targeted vaccination strategies are vital for protecting vulnerable populations and limiting transmission.
Did you grasp? Mpox, formerly known as monkeypox, can manifest as a rash affecting the face, anogenital region, palms, and soles of the feet, often accompanied by fever, headache, and swollen lymph nodes.
The Role of Travel and Global Health Security
The link between travel and mpox transmission highlights the importance of global health security. Strengthening health infrastructure in endemic regions like Madagascar is crucial to prevent future outbreaks and limit international spread. Improved screening procedures at international airports and increased awareness among travelers can also play a significant role.
Expert Insight:
“The current situation in Réunion is a stark reminder that mpox remains a public health threat. A coordinated regional approach, coupled with targeted vaccination and robust surveillance, is essential to prevent further spread and protect vulnerable populations.” – Dr. [Fictional Public Health Expert Name], Global Health Institute.
Accessing Vaccination in Réunion
Vaccination is available by appointment at three centers in Réunion: Saint Paul (CEGIDD West), Saint-Denis (International Vaccination Center North-East), and Saint-Pierre (International Vaccination Center South).
Frequently Asked Questions
What are the symptoms of mpox?
Mpox typically presents as a rash, which can affect various parts of the body, and may be accompanied by fever, headache, muscle aches, or swollen lymph nodes.
Who is eligible for mpox vaccination in Réunion?
Currently, vaccination is prioritized for immunocompromised individuals, men who have sex with men (MSM), sex workers, travelers to Madagascar, and close contacts of confirmed cases.
How effective is the mpox vaccine?
The vaccine is highly effective in preventing mpox, particularly when administered within four days of exposure. It remains beneficial up to 14 days post-exposure.
Where can I find more information about mpox?
You can find more information from the Réunion Regional Health Agency and the World Health Organization (WHO). WHO Mpox Fact Sheet
What steps will you take to stay informed and prepared as mpox continues to evolve? The key is proactive awareness and access to reliable information.
